Monoamine Oxidase Inhibitors

MAO-A

MAO-B

Monoamine Oxidase Inhibitors

Product Name	MAO-A	MAO-B	Purity
Tranylcypromine hydrochloride	MAO-A, IC₅₀: 2.3 μM	MAO-B, IC₅₀: 0.95 μM	99.90%
Selegiline hydrochloride		MAO-B, IC₅₀: 51 nM	99.94%
LSD1/HDAC6-IN-2	MAO-A, IC₅₀: 5 nM	MAO-B, IC₅₀: 6600 nM	99.66%
Pargyline	MAO-A, Ki: 13 μM	MAO-B, Ki: 0.5 μM	99.77%
Pargyline hydrochloride	MAO-A, Ki: 13 μM	MAO-B, Ki: 0.5 μM	99.91%
Norharmane	MAO-A, IC₅₀: 6.5 μM	MAO-B, IC₅₀: 4.7 μM	99.46%
Moclobemide	MAO-A, IC₅₀: 6.061		99.90%
Rasagiline	rMAO-A, IC₅₀: 412 nM	rMAO-B, IC₅₀: 4.43 nM	99.88%
Safinamide	MAO-A, IC₅₀: 580 μM	MAO-B, IC₅₀: 98 nM	99.89%
Tedizolid phosphate	MAO-A	MAO-B	99.65%
Rasagiline mesylate	rMAO-A, IC₅₀: 412 nM	rMAO-B, IC₅₀: 4.43 nM	99.77%
Harmane	hMAO-A, IC₅₀: 0.5 μM	MAO-B, IC₅₀: 5 μM	99.91%
Harmol		MAO-B	99.77%
Safinamide mesylate	MAO-A, IC₅₀: 580 nM	MAO-B, IC₅₀: 98 nM	99.87%
Osthenol	hMAO-A, Ki: 0.26 μM hMAO-A, IC₅₀: 0.74 μM		99.27%
MAO-IN-M30 dihydrochloride	MAO-A, IC₅₀: 37 nM	MAO-B, IC₅₀: 57 nM	99.25%
(E)-8-(3-Chlorostyryl)caffeine		MAO-B, Ki: 70 nM	99.00%
Methyl citrate		MAO-B, IC₅₀: 0.23 mM	≥98.0%
MAO-B-IN-25	MAO-A, IC₅₀: 240 nM	MAO-B, IC₅₀: 0.5 nM	99.11%
Bifemelane hydrochloride	MAO-A, Ki: 4.2 μM	MAO-B, Ki: 46 μM	99.86%
MAO-B-IN-18	hMAO-A, IC₅₀: 14 μM	hMAO-B, IC₅₀: 52 nM	99.84%
Ladostigil hydrochloride		MAO-B, IC₅₀: 37.1 μM	99.94%
Chrysophanol-1-O-β-gentiobioside	MAO-A, IC₅₀: 96.15 μM		≥99.0%
Ladostigil hemitartrate		MAO-B, IC₅₀: 37.1 nM	98.90%
TC-2153	MAO-A		98.73%
MAO-A/5-HT2AR-IN-1	MAO-A, IC₅₀: 0.004 ± 0. μM	MAO-B, IC₅₀: 1.05 ± 0.0 μM	99.71%
Ladostigil		MAO-B, IC₅₀: 37.1 μM
MAO-A inhibitor 1	MAO-A, IC₅₀: 100 μM
ASS234	MAO-A, IC₅₀: 5.2 nM	MAO-B, IC₅₀: 43 nM
(Rac)-Rasagiline		MAO-B
Tetrindole mesylate	MAO-A		99.93%
Selegiline		MAO-B, IC₅₀: 51 nM
MAO A/HDAC-IN-1	MAO-A
hMAO-B-IN-7		hMAO-B, IC₅₀: 0.79 μM
MAO-B-IN-21		MAO-B
Befloxatone	MAO-A, IC₅₀: 4 nM	MAO-B, IC₅₀: 300 nM
Dual AChE-MAO B-IN-2		MAO-B, Ki: 4.5 μM
AChE-IN-60	MAO-A, IC₅₀: 353 nM	MAO-B, IC₅₀: 716 nM
MAO-A inhibitor 2	MAO-A, IC₅₀: 14.3 μM	MAO-B, IC₅₀: 106 μM
MAO-B-IN-9		MAO-B, IC₅₀: 0.178 ± 0. μM	99.70%
ChEs/MAOs-IN-2	MAO-A, IC₅₀: 0.10 μM	MAO-B, IC₅₀: 0.20 μM
Esuprone	MAO-A, IC₅₀: 7.3 nM
LSD1-IN-17	MAO-A, IC₅₀: 0.028 ± 0. μM	MAO-B, IC₅₀: 0.820 ± 0. μM
(±)-Amiflamine	MAO-A, pIC₅₀: 5.57		99.23%
MAO-B-IN-13		MAO-B, IC₅₀: 10 nM
Cimoxatone	MAO-A
LSD1-IN-34	MAO-A, IC₅₀: 18.46 nM	MAO-B, IC₅₀: 8481.67 nM
PSB-1491		hMAO-B, IC₅₀: 0.0386 nM
Neuroinflammatory-IN-2		MAO-B, IC₅₀: 10.30 μM
AChE/BChE/MAO-B-IN-3		hMAO-B, IC₅₀: 0.0359 μM
MAO-B-IN-33	MAO-A, IC₅₀: 26.805 μM	MAO-B, IC₅₀: 0.021 μM
AChE/MAO-IN-1	hMAO-A, IC₅₀: 0.1108 μM hMAO-A, Ki: 0.1069 μM	hMAO-B, IC₅₀: 0.0409 μM
hMAO-B-IN-2		MAO-B, IC₅₀: 4 nM
MAO-B-IN-16	hMAO-A, IC₅₀: ＞100 μM	hMAO-B, IC₅₀: 1.55 μM
1-Methyl-2-undecyl-4(1H)-quinolone		MAO-B, IC₅₀: 15.3 μM MAO-B, Ki: 9.91 μM
LSD1-IN-15	MAO-A, IC₅₀: 0.028 ± 0. μM	MAO-B, IC₅₀: 0.327 ± 0. μM
CHBO4		hMAO-B, IC₅₀: 0.031 μM
MAO-B-IN-7		MAO-B, IC₅₀: 0.3 μM
MAO-B-IN-14		hMAO-B, IC₅₀: 0.95 μM hMAO-B, Ki: 0.55 μM
AChE/BChE/MAO-B-IN-2		MAO-B, IC₅₀: 48.2 nM
MAO-B ligand-1	hMAO-A, IC₅₀: 22.57 nM	hMAO-B, IC₅₀: 3.83 nM
MAO-B-IN-8		MAO-B	98.03%
AChE/MAO-B-IN-3		hMAO-B, IC₅₀: 0.0456 μM
MAO-B-IN-11		MAO-B, IC₅₀: 1.3 μM
MAO-B-IN-10	MAO-A, IC₅₀: 15.9 ± 0.1 μM	MAO-B, IC₅₀: 5.3 ± 0.22 μM
Multitarget AD inhibitor-2		MAO-B, IC₅₀: 0.45 μM
Desoxypeganine	MAO-A, IC₅₀: 2 μM
HDAC1/MAO-B-IN-1		MAO-B, IC₅₀: 99.0 nM
MAO-B-IN-3		MAO-B, IC₅₀: 96 nM
MAO-B-IN-5	MAO-A, IC₅₀: 0.204 μM	MAO-B, IC₅₀: 34.190 μM
LSD1-IN-26	MAO-A, IC₅₀: 1234.57 nM	MAO-B, IC₅₀: 3819.27 nM
Dual AChE-MAO B-IN-3		MAO-B, IC₅₀: 0.41 ± 0.0 μM
2-PAT	MAO-A, IC₅₀: 0.721 μM	MAO-B, IC₅₀: 14.6 μM
MAO-B-IN-31		MAO-B, IC₅₀: 41 nM
Harmane (Standard)	hMAO-A	MAO-B
Tetrahydroharmine		MAO-B, IC₅₀: 74 nM	98.00%
NDs-IN-1	hMAO-A	hMAO-B
MAO-B-IN-20	MAO-A, IC₅₀: >10 μM	MAO-B, IC₅₀: 0.037 μM
AChE/BChE-IN-6		hMAO-B, IC₅₀: ＞ 100 μM
1-Methyl-2-nonyl-4(1H)-quinolone	MAO-A	MAO-B
MAO-B-IN-17	hMAO-A, IC₅₀: >100 μM	hMAO-B, IC₅₀: 5.08 μM	≥99.0%
MAO-B-IN-32		MAO-B, IC₅₀: 16 nM
AChE/BuChE/MAO-B-IN-1		hMAO-B, IC₅₀: 1.11 μM
Moclobemide N-Oxide	MAO-A
FTEAA	MAO-A, IC₅₀: 0.52 μM	MAO-B, IC₅₀: 1.02 μM
MAO A/HSP90-IN-2	MAO-A, IC₅₀: 4.58 μM
MAO-B-IN-6	MAO-A, IC₅₀: 46.365 μM	MAO-B, IC₅₀: 0.019 μM
MAO-B-IN-30	MAO-A, IC₅₀: 19.176 μM	MAO-B, IC₅₀: 0.082 μM	98.53%
Monoamine Oxidase B inhibitor 5	hMAO-A, IC₅₀: 26014 nM	hMAO-B, IC₅₀: 67.3 nM
LSD1-IN-12	MAO-A, Ki: 2.3 μM	MAO-B, Ki: 3.5 μM
AChE/BChE/MAO-B-IN-1		MAO-B, IC₅₀: 26.1 μM	99.57%
MAO-A/B-IN-3	MAO-A, IC₅₀: 67 nM	MAO-B, IC₅₀: 29 nM
MAO-B-IN-19		MAO-B, IC₅₀: 0.67 μM
MAO-B-IN-29		MAO-B
MAO-B-IN-15	hMAO-A, IC₅₀: >100 μM	hMAO-B, IC₅₀: 13.5 μM
Desoxypeganine hydrochloride	MAO-A, IC₅₀: 2 μM
AChE/MAO-B-IN-4		hMAO-B
Monoamine Oxidase B inhibitor 2	MAO-A, IC₅₀: 1150 nM	MAO-B, IC₅₀: 1.33 nM
H3R antagonist 2		MAO-B, IC₅₀: 775 nM
AChE/BuChE/MAO-B-IN-2		hMAO-B, IC₅₀: 1.9 μM
Monoamine Oxidase B inhibitor 1	MAO-A, IC₅₀: 810 nM	MAO-B, IC₅₀: 0.02 nM
MAO-A/SERT-IN-1	MAO-A
SL-25.1188		hMAO-B, Ki: 2.9 nM rMAO-B, Ki: 8.5 nM
Lazabemide hydrochloride		MAO-B, IC₅₀: 0.4 nM
AChE/MAO-IN-2	MAO-A, IC₅₀: 0.1116 μM	MAO-B, IC₅₀: 0.0412 μM
hAChE-IN-3		MAO-B, IC₅₀: 5.15 μM
MAO-B-IN-12		MAO-B, IC₅₀: 1.3 μM
COMT-IN-1	MAO-A, IC₅₀: 95.58 μM	MAO-B, IC₅₀: 58.82 μM
Methyl piperate		MAO-B
Monoamine oxidase/Aromatase-IN-1		MAO-B, IC₅₀: 39 nM
Eckol	hMAO-A, IC₅₀: 7.20 μM	hMAO-B, IC₅₀: 83.44 μM
Dual AChE-MAO B-IN-4		MAO-B, IC₅₀: 15 nM
LSD1-IN-16	MAO-A, IC₅₀: 0.024 ± μM	MAO-B, IC₅₀: 0.366 ± μM
PSB-1434		MAO-B, IC₅₀: 1.59 nM	98.05%
BChE/MAO-B-IN-1		MAO-B, IC₅₀: 20 nM
5-HT6R/MAO-B modulator 1		MAO-B
MAO A/HSP90-IN-1	MAO-A, IC₅₀: 1.77 μM
Tedizolid phosphate sodium	MAO-A	MAO-B
PSB-1410		hMAO-B, IC₅₀: 0.23 nM rMAO-B, IC₅₀: 1.01 nM
SZV-558		rMAO-B, IC₅₀: 50 nM hMAO-B, IC₅₀: 60 nM
Brofaromine hydrochloride	MAO-A
Acacetin 7-O-(6-O-malonylglucoside)	MAO-A, IC₅₀: 2.34 μM	MAO-B, IC₅₀: 1.87 μM
6,7-Dimethylisatin	MAO-A, IC₅₀: 20.3 μM	MAO-B, IC₅₀: 6.74 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.